Biparametric MRI as initial screening method less cost-effective for prostate cancers compared to screening with PSA: Study
A new study published in the Annals of Internal Medicine suggests that a cost-effectiveness analysis revealed that using biparametric magnetic resonance imaging (MRI) as the initial screening method for prostate cancer is less cost-efficient when compared to starting with prostate-specific antigen (PSA) testing followed by multiparametric MRI as a second step.
The research team developed a microsimulation model to assess the effectiveness and costs of using first-line biparametric MRI versus first-line PSA with subsequent multiparametric MRI for prostate cancer screening. The model simulated biennial screening up to age 69 after comparing initial PSA testing (positive threshold of 4 mg/L) with or without second-line multiparametric MRI against first-line biparametric MRI (positive threshold PI-RADS score of 3 to 5 or 4 to 5), followed by biopsy guided by MRI or MRI plus transrectal ultrasonography.
The key findings of this study indicated that first-line MRI-based screening significantly increased the rates of false-positive tests, prostate biopsies, and over diagnosis without correspondingly reducing prostate cancer mortality. For every 1,000 men screened, first-line biparametric MRI prevented 2 to 3 prostate cancer deaths and added 10 to 30 life-years (equivalent to 4 to 11 days per person). However, it also resulted in 1,506 additional biopsies and 38 to 124 more over diagnoses, depending on the biopsy imaging scheme. The study found that, at conventional cost-effectiveness thresholds, first-line PSA testing followed by multiparametric MRI and either biopsy method yielded the highest net monetary benefits.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.